PreveCeutical Medical (Seite 8)
eröffnet am 04.10.18 20:07:39 von
neuester Beitrag 23.03.24 07:34:19 von
neuester Beitrag 23.03.24 07:34:19 von
Beiträge: 864
ID: 1.289.874
ID: 1.289.874
Aufrufe heute: 0
Gesamt: 30.064
Gesamt: 30.064
Aktive User: 0
ISIN: CA74141E1043 · WKN: A2DU8Q
0,0190
EUR
-5,00 %
-0,0010 EUR
Letzter Kurs 11:43:47 Lang & Schwarz
Neuigkeiten
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5500 | +33,50 | |
| 1,6240 | +29,71 | |
| 1,6600 | +23,88 | |
| 8,0000 | +20,30 | |
| 0,8600 | +17,81 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,4400 | -14,79 | |
| 3,8900 | -15,07 | |
| 0,5925 | -15,36 | |
| 0,9801 | -16,23 | |
| 2,1400 | -23,57 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 73.142.860 von DrMoeller am 23.01.23 13:06:30Wunderbar. Die Serie gebt weiter
Weitere sehr gute News über Patente, es lohnt noch nachzukaufen !!!
https://ceo.ca/@newsfile/preveceutical-background-ip-us-pate…
Articles@newsfile/preveceutical-background-ip-us-patent-granted-disulfide channel
0 online Today This week
by @newsfile on 23 Jan 2023, 07:00
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's commercialization company) has granted PreveCeutical exclusive rights to the platform technology. The US patent protects the disulfide linker platform technology, which is used in peptides forming part of PreveCeutical's BSV (blue scorpion venom) peptide program, Non-Analgesic Dynorphin (Painkiller) and D&O (Diabetes & Obesity) Gene Therapy siRNA program.
Grant of this patent is a key component, foundation and building block of PreveCeutical's IP strategy in the development of three of its four therapeutic programs.
PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "We are very pleased with the US grant of this patent to the University of Queensland as this technology is important to PreveCeutical for possible therapies for BSV Peptides, Dynorphin Peptides, and Diabetes and Obesity Gene Therapy. This will contribute towards the US protection of the linker technology as we further develop our IP and clinical research towards the commercialization of possible therapies."
0 online Today This week
by @newsfile on 23 Jan 2023, 07:00
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's commercialization company) has granted PreveCeutical exclusive rights to the platform technology. The US patent protects the disulfide linker platform technology, which is used in peptides forming part of PreveCeutical's BSV (blue scorpion venom) peptide program, Non-Analgesic Dynorphin (Painkiller) and D&O (Diabetes & Obesity) Gene Therapy siRNA program.
Grant of this patent is a key component, foundation and building block of PreveCeutical's IP strategy in the development of three of its four therapeutic programs.
PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "We are very pleased with the US grant of this patent to the University of Queensland as this technology is important to PreveCeutical for possible therapies for BSV Peptides, Dynorphin Peptides, and Diabetes and Obesity Gene Therapy. This will contribute towards the US protection of the linker technology as we further develop our IP and clinical research towards the commercialization of possible therapies."
Antwort auf Beitrag Nr.: 73.106.559 von jetset0711 am 17.01.23 14:31:29Der Newsflow müsste weiter gehen.
Antwort auf Beitrag Nr.: 73.105.908 von Hamburgerjung89 am 17.01.23 13:18:38Schauen wir mal wann die Rakete zündet! Zeit wäre es! ✌️😃
Trading Spotlight
Wunderbar. News kommen 
PreveCeutical ® Medical Inc. (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is a
preventive health sciences company with its corporate office in Vancouver,
Canada, subsidiary PreveCeutical (Australia) Pty Ltd is in Brisbane, Australia.
Utilizing innovative science and cutting-edge technology to enhance natural
products for novel targeted therapeutics, the company is developing a diverse
portfolio of research and development programs addressing significant market
diseases. The company's focus is on developing genetically identical products
and therapies for health-conscious consumers and becoming a trusted provider
of preventive health solutions globally.
The company intends to secure the market share through a business-to-business
strategy to build an extensive library of intellectual properties and enter into a
joint venture, development and licensing agreements with leaders in the
pharmaceutical and cannabis industries.
PreveCeutical's team of experienced senior executives and scientists envision
the medical community transitioning from systems that treat people after they
have become ill to those of personalized, preventive-based treatments.
R&D programs are with UniQuest, the commercialization arm of the University of
Queensland. The programs are led by Dr. Harendra Parekh, PreveCeutical's Chief
Research Officer and a UQ researcher. All intellectual property developed during the
programs will be owned by PreveCeutical.
OVERVIEW
CSE: PREV
OTCQB: PRVCF
FSE: 18H
LEADERSHIP TEAM
Stephen Van Deventer
Chairman & CEO (Canada)
Chairman & Director (Australia)
Mak Jawadekar, PhD
President, Chief Science Officer &
Director (Canada)
Linnéa Olafsson, PhD
Director (Canada)
Kathy Rokita, CPA
Director (Canada)
Shabira Rajan, MBA, CPA, CGA
Chief Financial Officer & Controller
(Canada)
Chief Financial Officer & Director
(Australia)
James Henderson
Director (Australia)
Harry Parekh, PhD, BSc Hons
Chief Research Officer (Canada)
ADVISORY BOARD
Ajit Shetty, PhD • extensive pharmaceutical
experience leading commercial
and supply chain operations.
Aditya Bahl • over 20 years of experience in
pharmaceutical marketing and
clinical development and is
known for his entrepreneurship
and creativity.
CSE: PREV | OTCQB: PRVCF | FSE: 18H
WWW.PREVECEUTICAL.COM
PreveCeutical ®
is able to employ
the Linker
Technology, a
proprietary one-step
synthesis that
prevents
degradation.
Resulting in a
Nature Identical™
product that can
effectively be
manufactured as the
market demands.
PIPELINE
Sol-Gel Delivery
Nose-to-Brain Delivery of Therapeutic Cannabinoids
• Water soluble, patient safe, cannabinoid formulations for the
clinical relief of a range of indications from pain to neurological
disorders.
Non-Addictive Analgesic
Engineering Non-Addictive Analgesic Peptides for Pain Management.
• Developing high biostable peptides to substitute dependenceassociated
opioids such as morphine, fentanyl and oxycodone.
BSV Peptide Program
Targeting cancer progression.
• Developing highly biostable peptides aiming to treat, regulate
and prevent cancer progression.
Dual Gene Therapy
Targeting Type 2 Diabetes and Obesity
• Targeting the over-expression of a gene that drives the
manifestation of insulin resistance and accumulation of fatty
preventive health sciences company with its corporate office in Vancouver,
Canada, subsidiary PreveCeutical (Australia) Pty Ltd is in Brisbane, Australia.
Utilizing innovative science and cutting-edge technology to enhance natural
products for novel targeted therapeutics, the company is developing a diverse
portfolio of research and development programs addressing significant market
diseases. The company's focus is on developing genetically identical products
and therapies for health-conscious consumers and becoming a trusted provider
of preventive health solutions globally.
The company intends to secure the market share through a business-to-business
strategy to build an extensive library of intellectual properties and enter into a
joint venture, development and licensing agreements with leaders in the
pharmaceutical and cannabis industries.
PreveCeutical's team of experienced senior executives and scientists envision
the medical community transitioning from systems that treat people after they
have become ill to those of personalized, preventive-based treatments.
R&D programs are with UniQuest, the commercialization arm of the University of
Queensland. The programs are led by Dr. Harendra Parekh, PreveCeutical's Chief
Research Officer and a UQ researcher. All intellectual property developed during the
programs will be owned by PreveCeutical.
OVERVIEW
CSE: PREV
OTCQB: PRVCF
FSE: 18H
LEADERSHIP TEAM
Stephen Van Deventer
Chairman & CEO (Canada)
Chairman & Director (Australia)
Mak Jawadekar, PhD
President, Chief Science Officer &
Director (Canada)
Linnéa Olafsson, PhD
Director (Canada)
Kathy Rokita, CPA
Director (Canada)
Shabira Rajan, MBA, CPA, CGA
Chief Financial Officer & Controller
(Canada)
Chief Financial Officer & Director
(Australia)
James Henderson
Director (Australia)
Harry Parekh, PhD, BSc Hons
Chief Research Officer (Canada)
ADVISORY BOARD
Ajit Shetty, PhD • extensive pharmaceutical
experience leading commercial
and supply chain operations.
Aditya Bahl • over 20 years of experience in
pharmaceutical marketing and
clinical development and is
known for his entrepreneurship
and creativity.
CSE: PREV | OTCQB: PRVCF | FSE: 18H
WWW.PREVECEUTICAL.COM
PreveCeutical ®
is able to employ
the Linker
Technology, a
proprietary one-step
synthesis that
prevents
degradation.
Resulting in a
Nature Identical™
product that can
effectively be
manufactured as the
market demands.
PIPELINE
Sol-Gel Delivery
Nose-to-Brain Delivery of Therapeutic Cannabinoids
• Water soluble, patient safe, cannabinoid formulations for the
clinical relief of a range of indications from pain to neurological
disorders.
Non-Addictive Analgesic
Engineering Non-Addictive Analgesic Peptides for Pain Management.
• Developing high biostable peptides to substitute dependenceassociated
opioids such as morphine, fentanyl and oxycodone.
BSV Peptide Program
Targeting cancer progression.
• Developing highly biostable peptides aiming to treat, regulate
and prevent cancer progression.
Dual Gene Therapy
Targeting Type 2 Diabetes and Obesity
• Targeting the over-expression of a gene that drives the
manifestation of insulin resistance and accumulation of fatty
Antwort auf Beitrag Nr.: 73.089.263 von jetset0711 am 13.01.23 22:12:49
0.035CAD, habe alle an der Heimatbörse.
Zitat von jetset0711: Ufff… Wo hast die denn gekauft? Habe gerade bei L&S für 0,027 gekauft.
0.035CAD, habe alle an der Heimatbörse.
Ja ich denke die USA wären gut wegen der dortigen opiod Krise, es stehen extrem viele Mittel zur Verfügung im eine alternative zu finden, deshalb grosse Chance
Durchsuchen
